Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai's Regional Shift, Or Just Restructuring? Daiichi Sankyo's U.S. Ranbaxy Dip: Japanese Earnings Roundup (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

[Editor's note: This is part two of a two-part feature on Japanese pharma earnings; part one covered Dainippon Sumitomo Pharma Co. Ltd. and its failed pan-Asia trials and Mitsubishi Tanabe Pharma Corp.'s efforts to rebound from Japan's March 11 earthquake. This second part covers Eisai Co. Ltd. and Daiichi Sankyo Co. Ltd.]

You may also be interested in...



Dainippon Sumitomo's Pan-Asia Trial Problem; Mitsubishi Tanabe Tries To Rebound From Earthquake: Japanese Earnings Roundup (Part 1)

TOKYO - Dainippon Sumitomo Pharma Co. Ltd. has a lot riding on anticipated blockbuster Latuda (lurasidone); for the 2011 fiscal year, the company forecasts sales will plunge 4.6% to ¥362 billion due to sales decreases in its major products. Such is the importance of the schizophrenia drug that the company announced during its May 12 full-year earnings call a post-Latuda strategy, even though the schizophrenia drug just launched in the U.S. in February

Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers

TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training

Daiichi Sankyo To Revamp Prasugrel's U.S. Marketing After Sluggish Sales

TOKYO - An 11.1 percent upward operating income revision to ¥100 billion notwithstanding, Daiichi Sankyo is streamlining its U.S. marketing strategy for platelet inhibitor Effient (prasugrel) as the drug's July-September U.S. and European sales remained a humble ¥1.8 billion, a company spokesman said Nov. 2

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel